About Regenesis
Regenesis is a Healthcare company based in Scottsdale (United States) founded in 1996. At-home non-drug pain relief devices are provided for patients. Regenesis has raised $13.32 million across 4 funding rounds from investors including Solstice Capital, Fulcrum Equity Partners and TGap Ventures. Its chief executive, as recorded, is Tom Eisiminger. Regenesis offers products and services including Reprieve, Provant, and Infinity. Its focus areas include Life Sciences, Pain Management, Medical Devices and Therapeutic Devices. Its competitors include Organogenesis, Sofregen and Encellin; 3 of its 3 listed competitors have raised funding.
Company details
Regenesis was founded in 1996 in Scottsdale, United States, and operates in the medical devices sector focused on pain management. At-home solutions without drugs are delivered through electromagnetic shortwave diathermy therapy devices. Products offered include Reprieve 60, Reprieve Duo, and Reprieve, which support patient care in non-clinical settings across the United States.
- Headquarters Scottsdale, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website regenesismed.com
- Social LinkedIn X Facebook YouTube
- Total Equity Funding$13.32M (USD)
in 4 rounds
- Latest Funding Round$5.2M (USD), Series C
Jun 2011
- InvestorsSolstice Capital
& 4 more
Products & Services of Regenesis
Regenesis offers a comprehensive portfolio of products and services, including Reprieve, Provant, and Infinity.
Electromagnetic therapy for non-drug home pain relief.
Home-based system for pain management support.
Advanced tool for electromagnetic pain relief.
Apps and channels of Regenesis
its YouTube channel Regenesis has 272 subscribers and 12 videos.
Videos from Regenesis
The most watched videos on Regenesis's YouTube channel, Regenesis (272 subscribers). Click a video to play it here.
More on Regenesis.
Funding Insights of Regenesis
Regenesis has successfully raised a total of $13.32M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $5.2 million completed in June 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.32M
- Total Rounds 4
- Last Round Series C — $5.2M
- First Round $3.2M
(Apr 2002)
- Investors Count 5
All 4 funding rounds of Regenesis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2011 | $5.2M | Series C | – | Fulcrum Equity Partners, TGap Ventures | |
| Jun 2007 | $2.79M | Series B | – | – | |
| Jun 2005 | $2.13M | Series B | – | – | |
| Apr 2002 | $3.2M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Regenesis
Regenesis has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Solstice Capital, Fulcrum Equity Partners and TGap Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are managed across the United States. | fulcrumep.com | Atlanta, United States | ||
US focused seed & early stage Micro VC firm | 1995 | solcap.com | Salem, United States | |
TGap Ventures is engaged in venture capital investments for startups. | tgapvcfunds.com | Kalamazoo, United States | ||
FinTech & Media focused seed and early stage VC firm investing in the US | villageventures.com | Williamstown, United States | ||
| valleyventures.com |
Investor details for Regenesis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Regenesis
1 people are tracked at Regenesis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Tom Eisiminger | CEO | Leadership |
Complete people profiles for Regenesis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Regenesis
3 dated milestones of Regenesis across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Regenesis is founded.
- Funding First funding round of $3.2M.
- Funding Latest funding round, Series C, of $5.2M.
Competitors of Regenesis
Regenesis has 3 listed competitors in our database, 3 of them funded. They include Organogenesis, Sofregen and Encellin.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| organogenesis.com | 1985 | Canton, United States | $30M | 856 | Regenerative therapies for wound care are developed and commercialized. | |
| sofregen.com | 2014 | Medford, United States | $17.8M | 8 | Silk-derived biomaterials are developed for soft tissue repair in surgery. | |
| encellin.com | 2015 | San Francisco, United States | $18.45M | Developer of regenerative materials |
Detailed competitors of Regenesis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Regenesis
The website of Regenesis (regenesismed.com) receives about 2K visits a month.
- Monthly visits2K
▲ 8.2% vs previous month
Top companies in Wound Care
3 companies that operate in the same segment as Regenesis (Wound Care) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | 35 | ||
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | USD 418.63 M | 837 | ||
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Regenesis
Complete news archive for Regenesis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regenesis
Regenesis was founded in 1996 and raised its 1st funding round 6 years after it was founded.
Regenesis is headquartered in Scottsdale, United States. It is registered at Scottsdale, Arizona, United States.
Tom Eisiminger is the CEO of Regenesis, as recorded in our data.
Regenesis is a funded company, having raised a total of $13.32M across 4 funding rounds to date. The company's 1st funding round was a Series A of $3.2M, raised on Apr 2002.
Regenesis was founded in 1996 in Scottsdale, United States, and operates in the medical devices sector focused on pain management. At-home solutions without drugs are delivered through electromagnetic shortwave diathermy therapy devices. Products offered include Reprieve 60, Reprieve Duo, and Reprieve, which support patient care in non-clinical settings across the United States.
Regenesis's top competitors include Organogenesis, Sofregen and Encellin.
Regenesis offers Reprieve, Provant, and Infinity.
Regenesis has 5 investors. Key investors include Solstice Capital, Fulcrum Equity Partners, TGap Ventures, Village Ventures, and Valley Ventures.